GlassScriptPhysician profile
Michael Andrew Garbee
NPI 1093923146
$3,864.50
in general payments reported to CMS, 2019-2025
35 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $234 · 2021: $775 · 2022: $842 · 2023: $95.83 · 2024: $1,403 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.56 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396.68 | 2021-2025 | |
| Lilly USA, LLC | $353.30 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Novartis Pharmaceuticals Corporation | $347.16 | 2020-2024 | |
| Amgen INC. | $329.83 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $258.93 | 2022-2024 | Austedo Xr, Ajovy |
| Pfizer INC. | $239.25 | 2024 | |
| Genzyme Corporation | $183.72 | 2019-2025 | |
| Lundbeck LLC | $181.23 | 2024-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $179.21 | 2022-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $129.82 | 2024-2025 | Ingrezza |
| Argenx US, INC. | $122.38 | 2024-2025 | Vyvgart Hytrulo |
| Sk Life Science, INC. | $108.28 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $90.11 | 2022 | |
| Acadia Pharmaceuticals INC | $82.04 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.22 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $76.19 | 2021-2022 | |
| Ucb, INC. | $74.26 | 2021 | |
| Tanabe Pharma America, INC. | $66.05 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $64.23 | 2024 | Purified Cortrophin Gel |
| Biogen, INC. | $63.89 | 2021-2022 | |
| Eisai INC. | $62.35 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $44.82 | 2021 | |
| Mallinckrodt Enterprises LLC | $44.22 | 2019 | |
| Amneal Pharmaceuticals LLC | $43.49 | 2021 | |
| Avanir Pharmaceuticals, INC. | $42.55 | 2022 | |
| Life Molecular Imaging LTD | $32.36 | 2019 | |
| Allergan, INC. | $28.83 | 2020 | |
| Arbor Pharmaceuticals, INC. | $25.32 | 2020-2021 | |
| Catalyst Pharmaceuticals, INC. | $22.84 | 2022 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Calliditas Therapeutics US INC. | $16.96 | 2022 | |
| Ge Healthcare | $15.44 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.06 | 2024 | Nuedexta |
| Genentech USA, INC. | $12.01 | 2019 | |
| Bioventus LLC | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Garbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.